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Interleukin-6 (IL-6) is a cytokine that has a wide variety of
biological activities involved in the immune response, acute
inflammation and haematopoiesis (Kishimoto, 1989). The cell
types producing IL-6 are systemically distributed: T-cells, B-
cells, monocytes, fibroblasts, keratinocytes, endothelial cells,
and several tumour cells (Ray et al., 1989). IL-6 production in
T-cells is induced by T-cell mitogens such as phorbol esters
or concanavalin A and antigenic stimulation on direct con-
tact with macrophages (Horii et al., 1988). Several T-cell
lines, however, transformed by human T-cell lymphotropic
virus type I (HTLV-I) express IL-6 mRNA without stimula-
tion (Hirano et al., 1986; Noma et al., 1989). Adult T-cell
leukaemia (ATL) is causally associated with HTLV-I infec-
tion and some ATL-cells produce or respond to lymphokines
such as IL-1 (Kodaka et al., 1989), IL-2 (Tsuda & Takatsuki,
1983; Arima et al., 1987), and IL-4 (Uchiyama et al., 1988).
In this study, we attempted to elucidate whether ATL-cells
secrete IL-6 or proliferate in response to this factor.
Blood samples were obtained from healthy volunteers and
patients with ATL admitted to Kumamoto University Hos-
pital between April 1988 and November 1989. The sera were
cryopreserved at -80°C until IL-6 measurement. The mono-
nuclear cells were separated from heparinised peripheral
blood of six acute ATL (designated as ATL 1-6) and four
normal controls and a cervical lymph node of one lymphoma
type ATL (ATL 7) by gradient centrifugation on Ficoll-
Hypaque. Surface phenotypes of the mononuclear cells as
analysed by flow cytometry are shown in Table I. Further-
more, T-cell enriched preparations were obtained by a sheep
red blood cell rosetting technique (Tsuda & Takatsuki, 1984).
Purity of T-cells as evaluated by flow cytometry of FITC-
conjugated anti-CD2-stained cells was 99% for ATL-cells
and 90% for normal controls. T-cells were cultured in 96-well
culture plates (2001il per well) at a concentration of 1 x 106
cells ml-' in RPMI 1640 containing 10% fetal calf serum in
the absence of additional factors. Recombinant human IL-6
(1-2 x 107 u mg-') and polyclonal anti human IL-6 antibody
were obtained from Amersham (Arlington Heights, IL, USA)
and R & D Systems (Minneapolis, MN, USA), respectively.
An ELISA kit (Inter-Test 6, Genzyme Corporation, Boston,
MA, USA) was used for the measurement of IL-6 in sera and
conditioned media (CMs).
First, the sera of both healthy volunteers (n = 6) and ATL
patients of different types or phases of disease (Kawano et
al., 1985); acute (n = 9), chronic (n = 10), smouldering
(n = 7), and lymphoma (n = 1) type, were tested for IL-6
levels. In the case of ATL, the patients with sepsis or
endotoxemia were omitted because serum IL-6 levels are
known to be enhanced in such conditions (Hack et al., 1989).
Results showed that not only control sera but also ATL sera
from all four categories of ATL patient did not have detec-
table levels of IL-6 (data not shown) (limit of sensitivity is
0.163 ng ml1' or 0.815 u ml-').
Next, in order to clarify whether ATL-cells do secrete IL-6
in vitro, CMs sampled at 2, 4, 8 and 24 h following culture
were tested for IL-6 concentrations. As shown in Figure 1,
two cases of ATL-CMs (ATL 1 and 2) showed obvious high
levels of IL-6 as compared with CMs of normal T-cells at 8
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and 24 h, and the case secreting the largest amount of IL-6
(ATL 1) was positive by 4 h. Another two cases (ATL 3 and
4) showed slightly higher IL-6 levels than controls at 8 and
24 h, but the last two cases (ATL 5 and 7) did not show
detectable levels of IL-6 even at 24 h. It is known that
IL-6 mRNA is induced in monocytes and T-cells within 5 h
and 24-48 h after culture initiation, respectively (Kishimoto,
1989). Considering the high purity of ATL cells used in the
study (Table I) and early detection of IL-6 at 4 or 8 h of
culture, the large amount of IL-6 detected in ATL-CMs
seemed to be secreted by ATL cells themselves. However,
normal T cells contaminated in the T cell preparations, if
activated, could have contributed some of the IL 6 that was
secreted into their cultures.
IL-6 promotes the growth of PHA-stimulated thymocytes
and peripheral T-cells (Kishimoto, 1989). To examine wheth-
er the IL-6 enhances proliferation of ATL-cells, ATL from
patients 1, 2, 5, 6 and 7 were incubated in the presence of
IL-6 (20 ng ml-') or anti-IL-6 antibody (200 u ml-') for 72 h;
proliferation was measured by 3H-thymidine (3H-TdR) incor-
poration in the last 16 h of culture. The 3H-TdR uptake into
ATL-cells was not influenced by either IL-6 or anti-IL-6
antibody (Table II).
Thus, we have demonstrated that ATL cells from four out
of six patients secreted IL-6 spontaneously in vitro and that
IL-6 was not detected in the sera of ATL patients in different
phases of the disease. HTLV-I infection activates genes for
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Figure 1 IL-6 levels in conditioned media of ATL-cells. Cells
(I x 106ml-') were incubated for indicated periods of time. IL-6
levels in conditioned media were determined by ELISA in dupli-
cates following the instructions of the manufacturer. The
horseradish peroxidase-mediated colour reaction was measured
by substracting absorbance at 650nm (A. 650) from that at
492 nm (A. 492). The screened columns represent ranges of IL-6
levels in normal T-cell-CM (mean ± s.d., n = 4). The broken line
show the lower limit of absorbance which can be converted to
IL-6 concentration using standard curve. The closed circle shows
IL-6 concentrations in complete medium used in cell culture.
Values beside each point indicate calculated IL-6 concentrations
(ng ml-').
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Table I Surface phenotypes of the mononuclear cells from ATL
patients
% Positive cellsa
Patients CD2 CD3 CD4 CD8 CD16 CD20 CD25
ATL 1 NTb 42.3 85.6 5.7 NT NT 20.4
2 99.9 99.2 99.6 7.7 0.2 0.0 78.1
3 99.6 96.4 91.9 5.4 4.1 0.2 88.6
4 98.1 51.9 96.4 1.9 NT 1.3 94.1
5 89.1 63.4 71.1 9.2 NT 9.4 45.2
6 97.7 74.6 88.5 6.3 2.7 0.4 73.7
7 99.0 29.7 98.6 0.8 NT 0.9 76.4
aThe cells were stained by the direct or indirect immunofluorescence
techniqueusingmonoclonal antibodies;OKT1 1,OKT3,OKT4, OKT8,
OKNK, Bi or anti Tac, then analysed by flow cytometer (Cytoron,
Ortho Diagnostic Systems, Tokyo, Japan) as described previously
(Tsuda & Takatsuki, 1983, 1984). bnot tested.
various cytokines and their receptors, but cytokine produc-
tion is not solely regulated by the virus genome (Noma et al.,
1989). Multiple elements induced in T-cells by HTLV-I infec-
tion seem to contribute to the production of IL-6. The gene
for IL-6 is located in chromosome 7p2l (Sehgel et al., 1986).
As the frequent chromosomal abnormalities of ATL are
observed in chromosome 7 (Ueshima et al., 1981), it is
intriguing to speculate on the presence of a relationship
between chromosome 7 abnormality and unregulated produc-
tion of IL-6 presented in this study.
Despite in vitro overproduction of IL-6 by ATL-cells, we
could not show detectable levels of IL-6 in the sera of ATL
patients. Although the reason for this discrepancy is unclear,
a more sensitive assay could show enhanced IL-6 levels in
ATL sera.
3H-TdR incorporation by ATL-cells was not affected by
IL-6 or anti-IL-6 antibody added exogenously. Nevertheless,
it is still possible that IL-6 may play an important role in the
growth of ATL-cells in vivo since IL-6 reportedly induced
IL-2 and IL-2 receptor expression in normal T-cells (Garman
et al., 1987; Tosato & Pike, 1988; Noma et al., 1987). How-
ever, our preliminary data suggest that expression of IL-2
receptor on ATL cells was not apparently affected by either
IL-6 or anti-IL-6 antibody (data not shown). In ATL, an
autocrine mechanism through IL-2 and IL-2 receptor is still
in debate (Tsuda & Takatsuki, 1983; Uchiyama et al., 1985;
Arima et al., 1987). The clinical features that accompany
ATL are diverse. Some of them may be explained by IL-6
production by ATL cells, such as the frequently observed
elevation of C-reactive protein (CRP), accelerated erythrocyte
sedimentation rate (ESR) and thrombocytosis (Castell et al.,
1989; Lotem et al., 1989). Thus unregulated IL-6 production
by ATL cells may be involved not only in pathogenesis but
also in major clinical manifestations of the disease.
Table 11 Effect of IL-6 and anti-IL-6 antibody on proliferation of ATL-cells
3H-Thymidine uptake (c.p.m. mean ± s.d.)
Patients None IL-6 (20 ngml') Anti-IL-6 (200 uml- )a
ATL 1 369 24 361 37 393± 29
2 401 6 434 41 416± 27
5 1880 167 1653 47 NTb
6 1231 176 1291 203 1317 ± 114
7 1559± 118 1485± 77 NT
normal control 1431 ± 126 1383 ± 123 1231 ± 17
aGne unit (u) anti-IL-6 corresponds to titre to neutralise 1 u IL-6; bNot tested.
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